Company intelligence / Profile preview
Italfarmaco
Milan, Italyitalfarmaco.com ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
01
Overview
Italfarmaco has demonstrated in clinical trials the increased risk of thrombosis in ambulatory patients undergoing chemotherapy for solid malignant tumors, and showed that nadroparine prophylaxis can halve this risk. They've also developed new therapeutic formulations for established molecules like riluzole for ALS, and paroxetine and zolpidem in drop form[6].
- Therapeutic areas
- CardiovascularRheumatologyImmunologyDermatologyWomen's HealthRare DiseasesNeurology
- Modalities
- Small moleculesPeptide drug conjugatesHumanized antibodies
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
03
Partnerships
Nerviano Medical Sciences
Beyond the preview
Go deeper on Italfarmaco.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Italfarmaco.